Grupo Español Multidisciplinar de Melanoma
12
4
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Role: lead
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Role: lead
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
Role: lead
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Role: lead
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Role: lead
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Role: lead
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Role: lead
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Role: lead
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Role: lead
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Role: lead
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
Role: lead
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
Role: lead
All 12 trials loaded